Silo Pharma Inc (SILO) Stock Price, Quote & News

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology

Sector: Healthcare

Phone: 718 400 9031

Website: silopharma.com

Address:

677 North Washington Boulevard, Sarasota, United States

Money_Too_Long Jun. 5 at 7:34 PM

$SILO For the average retail investor shorting this stock. Just stop it. It will take a larger institution to move the needle. Just let the damn stock fly.

0 · Reply

TheManUpstairs Jun. 4 at 4:50 PM

$SILO 👀

0 · Reply

Jbjb90 Jun. 4 at 1:03 PM

$SILO this stock is so easily moved post split, news on spc-15, share buyback, or the ibogaine patent and were back above ten. Cost to borrow shares short doubled from yesterday to today.

0 · Reply

topstockalerts Jun. 4 at 1:27 AM

$SILO didn’t expect this much follow-through

0 · Reply

Stock_Catcher Jun. 4 at 1:04 AM

New Video on the Bullish Analysis on $DRTS $NIO $BWEN $SILO $LAES and More https://www.youtube.com/watch?v=eONtec9txNY&t=4s

1 · Reply

focafoca99 Jun. 3 at 9:11 PM

$SILO effected a 1-for-15 reverse stock split, consolidating shares at a 15‑to‑1 ratio effective June 2, 2026.

0 · Reply

LewisDaKat Jun. 3 at 9:00 PM

$SILO US Companies Moving the Markets, Evening edition <br>Wed, Jun 03, 2026 as of 4:00 pm ET https://marketwirenews.com/stock/silo/news/us-companies-moving-the-markets-evening-edition-br-w-4746502495597168.html?utm_source=stocktwits

0 · Reply

TwongStocks Jun. 3 at 8:22 PM

Today's reverse split results. $SILO 1 for 15 Previous close $0.3501, $5.2515 split-adjusted Today's high $7.40 (premarket) Today's close $6.13 🟢Up 16.73%

0 · Reply

Jbjb90 Jun. 3 at 2:26 PM

$SILO $9 would be where we were when we had the executive order signing a few weeks back, .60 cents x 15 (R/S) = 9, just need some news

0 · Reply

Hfaistos Jun. 3 at 2:14 PM

$SILO Hopefully it will get to $7 by the EOW!

0 · Reply

Silo Pharma Inc trading halted, news pending

2026-05-07T18:37:18.000Z - 4 weeks ago

Silo Pharma files provisional patent for ibogaine-based therapeutics

May 7, 2026, 8:05 AM EDT - 4 weeks ago

Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury

Apr 29, 2026, 9:08 AM EDT - 5 weeks ago

Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD

2026-04-22T21:10:17.000Z - 6 weeks ago

Silo Pharma expands into AI technology with Qwikagents asset purchase

Apr 22, 2026, 4:15 PM EDT - 6 weeks ago

Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents

2026-04-06T20:20:47.000Z - 2 months ago

Silo Pharma gets European Patent Office allowance for PTSD prevention therapy

Apr 6, 2026, 4:15 PM EDT - 2 months ago

Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy

2026-02-23T21:38:21.000Z - 3 months ago

Silo Pharma announces $1M share repurchase program

Feb 23, 2026, 4:15 PM EST - 3 months ago

Silo Pharma Announces Share Buyback Program

2026-02-18T13:35:47.000Z - 3 months ago

Silo Pharma receives Notice of Allowance in Japan for SPC-15

Feb 18, 2026, 8:28 AM EST - 3 months ago

Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio

2025-12-30T13:35:34.000Z - 5 months ago

Silo Pharma executes LOI with Allucent for Phase 1 development of SPC-15

Dec 30, 2025, 8:05 AM EST - 5 months ago

Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15

2025-11-17T13:11:11.000Z - 7 months ago

Silo Pharma partners with Allucent for planned FDA IND application for SPC-15

Nov 17, 2025, 8:05 AM EST - 7 months ago

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD

2025-10-29T12:30:37.000Z - 7 months ago

Silo Pharma selects AlphaLedger’s T12 Fund for tokenized RWA investments

Oct 29, 2025, 8:25 AM EDT - 7 months ago

Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

2025-10-23T12:50:17.000Z - 8 months ago

Silo Pharma provides update on SPC-15 advancement, digital asset program

Oct 23, 2025, 8:45 AM EDT - 8 months ago

Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program

2025-10-08T12:51:28.000Z - 8 months ago

Silo Pharma announces initial Bitcoin purchase

Oct 8, 2025, 8:45 AM EDT - 8 months ago

Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth

2025-10-06T12:36:25.000Z - 8 months ago

Silo Pharma acquires ResearchCoin crypto tokens

Oct 6, 2025, 8:10 AM EDT - 8 months ago

Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)

Oct 1, 2025, 4:20 PM EDT - 8 months ago

Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2025-09-30T12:35:55.000Z - 8 months ago

Silo Pharma prices 2.86M shares at 87.5c in registered direct offering

Sep 30, 2025, 8:02 AM EDT - 8 months ago

Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

2025-09-29T18:35:25.000Z - 9 months ago

Silo Pharma updates strategic agreement with Fireblocks

Sep 16, 2025, 8:11 AM EDT - 9 months ago

Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy

Sep 9, 2025, 9:10 AM EDT - 9 months ago

Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

Sep 3, 2025, 8:25 AM EDT - 9 months ago

Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio

Aug 21, 2025, 2:00 PM EDT - 10 months ago

Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal

Aug 19, 2025, 8:05 AM EDT - 10 months ago

Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway

Aug 5, 2025, 8:32 AM EDT - 10 months ago

Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform

Jul 16, 2025, 8:45 AM EDT - 11 months ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 7, 2025, 8:15 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jun 25, 2025, 8:38 AM EDT - 1 year ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:27 AM EDT - 1 year ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 5, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

May 21, 2025, 8:55 AM EDT - 1 year ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 16, 2025, 4:15 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 1 year ago

Silo Pharma Announces Pricing of $2 Million Public Offering

May 14, 2025, 4:07 PM EDT - 1 year ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Apr 30, 2025, 8:11 AM EDT - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 28, 2025, 7:50 AM EDT - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Mar 26, 2025, 8:40 AM EDT - 1 year ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Feb 26, 2025, 1:30 PM EST - 1 year ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 18, 2025, 8:50 AM EST - 1 year ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 11, 2025, 7:45 AM EST - 1 year ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Jan 22, 2025, 8:29 AM EST - 1 year ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 2, 2025, 8:45 AM EST - 1 year ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Dec 18, 2024, 7:35 AM EST - 1 year ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Nov 29, 2024, 8:05 AM EST - 1 year ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 18, 2024, 8:40 AM EST - 1 year ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Oct 31, 2024, 8:35 AM EDT - 1 year ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Sep 10, 2024, 6:35 AM EDT - 1 year ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Jul 26, 2024, 8:20 AM EDT - 2 years ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 22, 2024, 4:45 PM EDT - 2 years ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 2 years ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 18, 2024, 8:25 AM EDT - 2 years ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Money_Too_Long Jun. 5 at 7:34 PM

$SILO For the average retail investor shorting this stock. Just stop it. It will take a larger institution to move the needle. Just let the damn stock fly.

0 · Reply

TheManUpstairs Jun. 4 at 4:50 PM

$SILO 👀

0 · Reply

Jbjb90 Jun. 4 at 1:03 PM

$SILO this stock is so easily moved post split, news on spc-15, share buyback, or the ibogaine patent and were back above ten. Cost to borrow shares short doubled from yesterday to today.

0 · Reply

topstockalerts Jun. 4 at 1:27 AM

$SILO didn’t expect this much follow-through

0 · Reply

Stock_Catcher Jun. 4 at 1:04 AM

New Video on the Bullish Analysis on $DRTS $NIO $BWEN $SILO $LAES and More https://www.youtube.com/watch?v=eONtec9txNY&t=4s

1 · Reply

focafoca99 Jun. 3 at 9:11 PM

$SILO effected a 1-for-15 reverse stock split, consolidating shares at a 15‑to‑1 ratio effective June 2, 2026.

0 · Reply

LewisDaKat Jun. 3 at 9:00 PM

0 · Reply

TwongStocks Jun. 3 at 8:22 PM

Today's reverse split results. $SILO 1 for 15 Previous close $0.3501, $5.2515 split-adjusted Today's high $7.40 (premarket) Today's close $6.13 🟢Up 16.73%

0 · Reply

Jbjb90 Jun. 3 at 2:26 PM

$SILO $9 would be where we were when we had the executive order signing a few weeks back, .60 cents x 15 (R/S) = 9, just need some news

0 · Reply

Hfaistos Jun. 3 at 2:14 PM

$SILO Hopefully it will get to $7 by the EOW!

0 · Reply

DARKP00L Jun. 3 at 1:11 PM

$SILO 08:55 on Jun. 03 2026 Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times #tradeideas

0 · Reply

Jbjb90 Jun. 3 at 1:06 PM

$SILO now would be a great time to implement the share buyback program, or if theyve been buying up the cheap shares pre split to announce something. Sold half my position, going to see if we sink or swim the rest of the week and either buy the other half here or lower

0 · Reply

tommy_john Jun. 3 at 12:29 PM

$SILO watch here

0 · Reply

FreeBeerTomorrow Jun. 3 at 7:25 AM

$SILO o Pharma, Inc. (SILO): Executing a 1-for-15 reverse split. This corporate action includes a concurrent proportional reduction of its authorized common stock. Shares begin trading on a post-split basis on Nasdaq this morning. Following the 1-for-15 consolidation, their total outstanding share count drops to approximately 1.084 million shares.

0 · Reply

TwongStocks Jun. 2 at 8:09 PM

Only one NASDAQ reverse split scheduled on Wednesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am ET Wednesday morning. $SILO 1 for 15. Will reduce outstanding shares from approx 16.27m to approx 1.08m.

0 · Reply

Adorno99 Jun. 1 at 10:45 PM

$SILO I think this is oversold in anticipation of the reverse split. May buy some down here to see if it holds it price after the split. Seems like a solid company otherwise

0 · Reply

TwongStocks Jun. 1 at 6:47 PM

$SILO Equity Corporate Actions Alert #2026 - 378 Information Regarding the Reverse Stock Split and CUSIP Number Change for Silo Pharma, Inc. (SILO) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-378 Silo Pharma, Inc. (SILO) will effect a one-for-fifteen (1-15) reverse split of its Common Stock. The reverse stock split will become effective on Wednesday, June 3, 2026. In conjunction with the reverse split, the CUSIP number will change to 82711P300.

0 · Reply

focafoca99 Jun. 1 at 1:21 PM

$SILO executed a 1-for-15 reverse stock split, cutting shares to roughly 1.084 million effective June 2, 2026.

0 · Reply

Jbjb90 Jun. 1 at 1:12 PM

$SILO was hoping theyd be able to avoid this 🤦‍♂️https://www.stocktitan.net/sec-filings/SILO/8-k-silo-pharma-inc-reports-material-event-040060b71c25.html

0 · Reply

Jbjb90 May. 29 at 2:37 PM

$SILO slow climb back up, just need news and volume, the quarterly results were better then i expected. 1.6 mil loss was bigger then expected, 6 mil cash equivalents, which funds them for at least 12 months which is solid. Hopefully back above .50 cents next week.

0 · Reply

Jbjb90 May. 27 at 1:26 PM

$SILO what happens to this now that hoth therapeutics is rocket one?

2 · Reply

Adorno99 May. 26 at 8:30 PM

$SILO looking good

0 · Reply

Market Cap	5.58M
Revenue (ttm)	70,000.00
Net Income (ttm)	-4.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-6,042.86%
Debt to Equity Ratio	0.00

Volume	29,500
Avg Vol	345,489
Day's Range	N/A - N/A
Shares Out	945,000.00
Stochastic %K	74%
Beta	0.63
Analysts	Strong Sell
Price Target	$10.00